Umbilical cord stem cell secreted product derived topical compositions and methods of use thereof
OwnerMichael Cohen, Jacob Coheninventors
Life of this patent
Estimating the term…
Abstract
Compositions including topical formulations comprising secreted products obtained from the culture medium of human umbilical cord stem cells and particular combinations of components therefrom are provided for treatment of various dermatological conditions, such as adverse consequences of aging, wrinkling, altered pigmentation, altered viscoelasticity, and altered thickness, among others. Methods for using the compositions and topical formulations for treating adverse or undesirable dermatological conditions are also provided, as well as preventing the appearance of undesirable dermatological conditions.
Claims26
A composition for application to the skin for the prevention or treatment of a skin condition, the composition comprising secreted products from umbilical cord stem cells, and a topically suitable carrier therefor.
A method for treating skin comprising applying to skin a topical composition comprising secreted products from human umbilical cord stem cells, and a dermatologically suitable carrier therefor.
A composition for application to the skin for the prevention or treatment of an adverse skin condition, the composition comprising elastase 2A;
- prostaglandin I2;
- prostaglandin E2;
- adam metallopeptidase with thrombospondin type 1 motif 5;
- bone morphogenetic protein 1;
- bone morphogenetic protein 6;
- chemokine (C—C motif) ligand 2;
- chemokine (C—C motif) ligand 20;
- chemokine (C—X—C motif) ligand 1;
- chemokine (C—X—C motif) ligand 2;
- chemokine (C—X—C motif) ligand 3;
- chemokine (C—X—C motif) ligand 5;
- chemokine (C—X—C motif) ligand 6;
- chemokine (C—X—C motif) ligand 9;
- colony stimulating factor 2;
- colony stimulating factor 3;
- gremlin 1, cysteine knot superfamily, homolog (Xenopus laevis);
- gremlin 2, cysteine knot superfamily, homolog (Xenopus laevis);
- heparin-binding EGF-like growth factor;
- natriuretic peptide precursor B;
- pleiotrophin;
- pre-B-cell colony enhancing factor 1;
- tumor necrosis factor (ligand) superfamily, member 4;
- and tumor necrosis factor receptor superfamily, member 11b.
A composition for application to the skin for the prevention or treatment of an adverse skin condition, the composition comprising elastase 2A;
- prostaglandin I2;
- prostaglandin E2;
- amphiregulin;
- fibroblast growth factor 2;
- fibroblast growth factor 7;
- G protein-coupled receptor, family C, group 5, member B;
- and GABA(a) receptor-associated protein like 1.
Dependencies are inferred from the claim text.